Michael A. Davies, MD, PhD

home / authors / michael-a-davies-md-phd

Articles

Michael A. Davies, MD, PhD

Dr. Davies on the Potential Utility of ERK Inhibitors in Melanoma

Michael A. Davies, MD, PhD
May 5th 2021

Michael A. Davies, MD, PhD, discusses the potential utility of ERK inhibitors in melanoma.

Read More

Michael A. Davies, MD, PhD, discusses the management of patients with melanoma during the COVID-19 pandemic.

Dr. Davies on Managing Melanoma During the COVID-19 Pandemic

Michael A. Davies, MD, PhD
April 28th 2021

Michael A. Davies, MD, PhD, discusses the management of patients with melanoma during the COVID-19 pandemic.

Read More

Michael A. Davies, MD, PhD

Dr. Davies on the Potential Role of Novel BRAF Inhibitors in Melanoma Brain Metastases

Michael A. Davies, MD, PhD
March 22nd 2021

Michael A. Davies, MD, PhD, discusses the potential role of novel BRAF inhibitors in treating patients with melanoma and brain metastases.

Read More

Michael A. Davies, MD, PhD, of The University of Texas MD Anderson Cancer Center

Dr. Davies on the Utility of Retreatment With BRAF/MEK Inhibitors in BRAF-Mutant Melanoma

Michael A. Davies, MD, PhD
February 24th 2021

Michael A. Davies, MD, PhD, discusses the utility of retreatment with combination BRAF/MEK inhibitors in BRAF-mutant melanoma.

Read More

Michael A. Davies, MD, PhD, of The University of Texas MD Anderson Cancer Center

Dr. Davies on Selecting Between Combination Regimens in BRAF-Mutant Melanoma

Michael A. Davies, MD, PhD
February 17th 2021

Michael A. Davies, MD, PhD, discusses factors to consider when selecting between combination regimens in BRAF-mutant melanoma.

Read More

Latest Updated Articles

Phase 1/2 ALKOVE-1 study of NVL-655 in ALK-positive (ALK+) solid tumors
Published: October 30th 2024 | Updated: November 7th 2024
Phase 1/2 ALKOVE-1 Study of NVL-655 in ALK-positive (ALK+) Solid Tumors
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Published: October 18th 2024 | Updated: October 21st 2024
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Published: October 14th 2024 | Updated: October 16th 2024
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Phase 1 trial of DLL3/CD3 IgG-Like T-Cell Engager BI 764532 in Patients with DLL3 Positive Tumors: Patients with LCNEC
Published: September 27th 2024 | Updated: October 9th 2024
Petosemtamab Plus Pembrolizumab vs. Pembrolizumab Alone for First-Line (1L) Treatment of Recurrent/Metastatic (R/M) PD-L1–Positive Head and Neck Squamous Cell Carcinoma (HNSCC): A Randomized, Open-Label, Phase 3 Trial
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Published: September 30th 2024 | Updated: October 4th 2024
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Real world evidence of treatment practices and therapeutic outcomes for newly diagnosed NSCLC patients with non-classical EGFR mutations demonstrates high unmet medical need
Published: September 27th 2024 | Updated: October 4th 2024
Real World Evidence of Treatment Practices and Therapeutic Outcomes for Newly Diagnosed NSCLC Patients With Non-Classical EGFR Mutations Demonstrates High Unmet Medical Need